



August 12, 2026

PeptiDream Inc.
<https://www.peptidream.com/en/>
(TSE Prime Market: 4587)

Initiation of Phase 1 Clinical Trial by Novartis Marks Milestone for PeptiDream

- *Phase 1 study of [¹⁷⁷Lu]Lu-DWJ155 and [⁶⁸Ga]Ga-DWJ155 being conducted in patients with breast cancer, lung cancer, gastric/gastroesophageal cancer, and bladder cancer.*
- *Milestone payment triggered upon clinical trial initiation by Novartis*

KAWASAKI, JAPAN – August 12, 2026 - PeptiDream Inc. ("PeptiDream"), a public biopharmaceutical company based in Kawasaki, Japan, focused on the discovery and development of peptide-based therapeutics, today marked a milestone following the initiation of a Phase 1 clinical study for [¹⁷⁷Lu]Lu-DWJ155 and [⁶⁸Ga]Ga-DWJ155, radioligand therapy ("RLT") targeting HER2 by Swiss-based Novartis Pharma AG (hereinafter "Novartis") (NYSE: NVS) in connection with the companies' 2019 research and collaboration agreement and PeptiDream's Peptide Discovery Platform System ("PDPS®").

The Phase 1 study is being conducted to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of [¹⁷⁷Lu]Lu-DWJ155 and the safety and imaging properties of [⁶⁸Ga]Ga-DWJ155 in patients with histologically or cytologically confirmed advanced HER2+, HR+/HER2-negative, or triple negative breast cancer ("TNBC"), non-small cell lung cancer ("NSCLC"), HER2-3+ or 2+ (ISH positive or negative) gastric/gastroesophageal junction ("GEJ") cancer, and bladder cancer. (ClinicalTrials.gov Identifier; NCT07660055).

The study will be done in two parts. The first part is called "escalation" and the second part is called "expansion". In both parts of the study, patients will initially be imaged with a [⁶⁸Ga]Ga-DWJ155 positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) scan. In the escalation part, different doses of [¹⁷⁷Lu]Lu-DWJ155 will then be tested to identify recommended dose(s) (RD(s)) for further evaluation. The expansion part of the study will examine the safety and preliminary efficacy of [¹⁷⁷Lu]Lu-DWJ155 at the RD(s) determined during the escalation part. In both parts, there will be a safety follow-up period after the last [¹⁷⁷Lu]Lu-DWJ155 administration.

*"The initiation of this Phase 1 study by Novartis represents another significant milestone in our discovery collaboration," said **Patrick C. Reid, Ph.D., President & CEO of PeptiDream**. "As the second program to enter clinical testing, it reflects the shared commitment, scientific excellence, and strength of collaboration between our teams."*

The initiation of the Phase 1 study triggered an undisclosed milestone payment from Novartis to PeptiDream, which will be accounted for in PeptiDream's FY26-Q3.

This initiation of the Phase 1 clinical trial has been factored in our consolidated financial forecasts for the fiscal year ending December 31, 2026, which was announced on February 16, 2026, and there are no changes to our forecast.

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS®) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en/

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Corporate Communications

Email: info@peptidream.com

Website: <https://www.peptidream.com/en/>

X: <https://x.com/PeptidreamInc>

LinkedIn: <https://www.linkedin.com/company/peptidream>